Launched in China in December 2021, Saiteshun is the first generic drug in the country passing the quality consistency evaluation, breaking the monopoly of imported counterparts in its class. It is used as part of a combination therapy for multidrug-resistant pulmonary tuberculosis (MDR-TB) in adolescents aged 12 to <18 years weighing ≥30 kg, as well as in adults (≥18 years) with MDR-TB.

Launched in China in 2014, Dasilikang is indicated in the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible to this drug and when treatment with the primary medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved inadequate.. It utilizes patented German packaging materials to ensure drug efficacy and shelf life of 30 months It’s a core therapeutic in the treatment of DR-TB.

Linaitong is an anti-infective medine imported from India. It received U.S. FDA approval in 2015 and was launched in China in November 2024. As one of the core drugs in regimens for drug-resistant tuberculosis, it is now widely used in the treatment of MDR-TB.

Approved in 2025, this product enables accurate monitoring of anti-tuberculosis drug concentrations through ultra-high performance liquid chromatography (UHPLC) technology, providing key support for individualized tuberculosis treatment. 

Besremi is an innovative ultra-long-acting interferon. Approved in China in June 2024, it is the first and only drug in China approved for the treatment of polycythemia vera (PV) in adults, filling the long-standing gap of no standardized therapeutic drugs in the domestic PV field. It is also the first innovative blood tumor drug deployed by our company.